TheWell Bioscience Information

TheWell Bioscience, Inc. delivers an end-to-end, xeno-free 3D cell culture platform enabling comprehensive, human-relevant 3D cell models to advance the future of biomedicine. Our platform bridges early discovery through clinical deployment by eliminating animal-derived materials and improving the biological fidelity of in vitro models—accelerating drug discovery, reducing experimental variability, and expanding the potential of personalized medicine. Our xeno-free ecosystem is built around a portfolio of innovative product families that work synergistically to advance 3D cell biology: • VitroGel® — Versatile, xeno-free, biofunctional hydrogels supporting a wide range of 3D cell culture and tissue models, such as organoid, 3D neuron, 3D iPSCs, spheroids, tumoroids, and more. • VitroINK® — Precision xeno-free bioinks engineered for reliable bioprinting and structured tissue assembly. • RocketCell™ — Robust xeno-free media and reagents that streamline cell expansion and 3D-ready workflows. • VitroPrime™ — Advanced surface-engineered plates for optimized 2D-to-3D hybrid culturing. • CytoGrow™ — Defined supplements and growth factors for controlled expansion and differentiation. • Cyto3D® — Innovative tools enabling standardized 3D cell analysis and quantifiable biological insights. Together, these product families power an integrated, end-to-end xeno-free platform that transforms how scientists model disease, engineer functional tissues, and translate 3D cell technologies into real-world clinical and commercial impact. Our approach aligns with New Approach Methodologies (NAMs) and the global shift toward predictive, human-relevant in vitro models—advancing ethical, reproducible, and translational research while reducing reliance on animal testing. Our mission is to unlock the full potential of 3D cell technology for clinical translation and laboratory automation—uniting biological precision with operational efficiency in a seamless, scalable ecosystem.